Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation

Kruspe, Sven; Meyer, Cindy; Hahn, Ulrich

doi:10.1038/mtna.2013.70

Cited by 47 publications

(43 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, the viability of IL-6R-positive cells was significantly inhibited under light irradiation due to ROS generation, while negligible cytotoxicity was found in IL-6R-negetive cells and cells treated with unconjugated Ce6 molecules. 258 …”

Section: Diverse Stimulationsmentioning

confidence: 99%

Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy

et al. 2016

View full text Add to dashboard Cite

Reactive oxygen species (ROS)-mediated mechanism is the major cause underlying the efficacy of photodynamic therapy (PDT). The PDT procedure is based on the cascade of synergistic effects between light, photosensitizer (PS) and oxygen, which greatly favor the spatiotemporal control of the treatment. This procedure has also evoked several unresolved challenges at different levels including (i) limited penetration depth of light restricts traditional PDT to only superficial tumours; (ii) oxygen reliance deprives PDT treatment of hypoxic tumours; (iii) light could complicate the phototherapeutic outcomes due to the concurrent heat generation; (iv) specific delivery of PSs to sub-cellular organelles for exerting effective toxicity remains an issue; and (v) side effects by undesirable white-light activation and self-catalysation of traditional PSs. Recent advances in nanotechnology and nanomedicine have provided new opportunities to develop ROS-generating systems through photodynamic or non-photodynamic procedures while tackling the challenges of current PDT approaches. In this review, we summarize the current status and discuss the possible opportunities of ROS generation for cancer therapy. We hope this review will spur pre-clinical research and clinical practice for ROS-mediated tumour treatment.

show abstract

Section: Diverse Stimulationsmentioning

confidence: 99%

Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy (PDT) is a treatment used to kill tumor cells whereby reactive oxygen species are generated in situ by the irradiation of light sensitive drugs called photosensitizers [134]. By conjugating the photosensitizer chlorin e6 to the human interleukin-6 receptor (IL-6R + )-binding aptamer, a targeted PDT probe was developed [135]. Human IL-6 is overexpressed in glioma cells and is implicated in glioma cell proliferation [136].…”

Section: Targets Related To Brain Cancer (Glioblastoma and Glioma)mentioning

confidence: 99%

Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System

McConnell

Holahan

DeRosa

2014

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.

show abstract

“…Toward this end, disease biomarker-targeting aptamers are promising for targeted delivery of photosensitizers. 67, 95, 134–140 …”

Section: Aptamer–photosensitizer Conjugatesmentioning

confidence: 99%

“…In a more recent study, an aptamer-photosensitizer conjugate was developed using Ce6 and an RNA aptamer, AIR-3A, that specifically binds to interleukin 6 receptor (IL-6R). 67 IL-6 and IL-6R are involved in various diseases ranging from inflammatory diseases such as Crohn’s disease, rheumatoid arthritis, psoriasis, systemic sclerosis, and some cancers. IL-6R-targeted drug delivery would thus be promising to selectively destroy the related targeted cells.…”

Section: Aptamer–photosensitizer Conjugatesmentioning

confidence: 99%

Aptamer–Drug Conjugates

2015

View full text Add to dashboard Cite

Western medicine often aims to specifically treat diseased tissues or organs. However, the majority of current therapeutics failed to do so owing to their limited selectivity and the consequent “off-target” side effects. Targeted therapy aims to enhance the selectivity of therapeutic effects and reduce adverse side effects. One approach toward this goal is to utilize disease-specific ligands to guide the delivery of less-specific therapeutics, such that the therapeutic effects can be guided specifically to diseased tissues or organs. Among these ligands, aptamers, also known as chemical antibodies, have emerged over the past decades as a novel class or targeting ligands that are capable or specific binding to disease biomarkers. Compared with other types or targeting ligands, aptamers have an array of unique advantageous features, which make them promising for developing aptamer–drug conjugates (ApDCs) for targeted therapy. In this Review, we will discuss ApDCs for targeted drug delivery in chemotherapy, gene therapy, immunotherapy, photodynamic therapy, and photothermal therapy, primarily of cancer.

show abstract

Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation

Cited by 47 publications

References 42 publications

Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy

Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy

Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System

Aptamer–Drug Conjugates

Contact Info

Product

Resources

About